Business Context and Reporting Period
This Form 8-K is a current report filed by AIT Therapeutics, Inc. (not Beyond Air, Inc., as noted in the metadata request) on January 2, 2019, covering events occurring on December 28, 2018, and January 2, 2019. The company is an emerging growth company incorporated in Delaware, focusing on medical technology, specifically a novel cylinder-free ventilator-compatible nitric oxide (NO) generator and phasic-flow delivery system known as GeNOvent*.
Key Financial Metrics
This filing is a report of "Other Events" and does not contain financial statements, revenue figures, profit data, cash flow information, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The filing reports two specific corporate events rather than financial changes:
- December 28, 2018: Issuance of a press release regarding the status of a proposed agreement to license commercial rights for the GeNOvent* system for hospital use at NO concentrations less than 80 ppm.
- January 2, 2019: Issuance of a press release announcing the appointment of a new Chief Commercial Officer.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, quantitative outlook, or detailed risk factors. It notes that the information contained in the press releases (Exhibits 99.1 and 99.2) is furnished and not filed for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the current status of the proposed licensing agreement for the GeNOvent* system referenced in the December 28, 2018 press release.
- Confirm the background and qualifications of the newly appointed Chief Commercial Officer.
- Review the full text of Exhibits 99.1 and 99.2 for details not summarized in the 8-K body.
- Note that the registrant is an emerging growth company, which may affect financial reporting requirements.